Dapagliflozin DELIVERs across full HF spectrum regardless of LVEF
The selective, oral sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin reduces the risk of cardiovascular (CV) death or worsening heart failure (HF) in patients with HF and mildly reduced or preserved ejection fraction (HFmrEF or HFpEF) in the phase III DELIVER* trial, touted as the largest and most inclusive thus far in this patient group.

New Molecule

3 New

New Formulation

2 New

New Brand

43 New

New Dosage Form

1 New

Markings
Shape
Form
Color 1
Color 2
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in